Literature DB >> 1277728

The clearance of antipyrine and indocyanine green in normal subjects and in patients with chronic lever disease.

R A Branch, J A James, A E Read.   

Abstract

The pharmacokinetics after oral administration of 1,200 mg antipyrine and intravenous administration of 0.5 mg/kg indocyanine green have been investigated in 6 normal subjects and in 20 patients with chronic liver disease of varying etiology. Severe impairment of liver function associated with a decrease in serum albumin, elevation in serum bilirubin, or prolongation in prothrombin time correlated with a fall in the clearance of both drugs. The clearance of the two drugs correlated well in normal subjects and in patients with chronic liver disease. The presence of a surgical portacaval anastomosis was associated with a lower indocyanine green clearance for comparable clearance of antipyrine. The concept of functioning hepatic parenchymal mass is proposed as a common rate-limiting parameter for the elimination of the two drugs.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1277728     DOI: 10.1002/cpt197620181

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  28 in total

Review 1.  Preclinical lymphatic imaging.

Authors:  Fan Zhang; Gang Niu; Guangming Lu; Xiaoyuan Chen
Journal:  Mol Imaging Biol       Date:  2011-08       Impact factor: 3.488

2.  Antipyrine clearance per unit volume liver: an assessment of hepatic function in chronic liver disease.

Authors:  M Homeida; C J Roberts; M Halliwell; A E Read; R A Branch
Journal:  Gut       Date:  1979-07       Impact factor: 23.059

Review 3.  Protein binding and kinetics of drugs in liver diseases.

Authors:  T F Blaschke
Journal:  Clin Pharmacokinet       Date:  1977 Jan-Feb       Impact factor: 6.447

4.  Identification of patients with impaired hepatic drug metabolism using a limited sampling procedure for estimation of phenazone (antipyrine) pharmacokinetic parameters.

Authors:  D Fabre; F Bressolle; R Goméni; O Bouvet; A Dubois; C Raffanel; J C Gris; M Galtier
Journal:  Clin Pharmacokinet       Date:  1993-04       Impact factor: 6.447

5.  Influence of nutritional status on plasma levels and relative bioavailability of tetracycline.

Authors:  T C Raghuram; K Krishnaswamy
Journal:  Eur J Clin Pharmacol       Date:  1977-12-02       Impact factor: 2.953

Review 6.  Drug prescribing in hepatobiliary disease.

Authors:  R K Roberts; P V Desmond; S Schenker
Journal:  Drugs       Date:  1979-03       Impact factor: 9.546

Review 7.  Propranolol disposition in chronic liver disease: a physiological approach.

Authors:  R A Branch; D G Shand
Journal:  Clin Pharmacokinet       Date:  1976       Impact factor: 6.447

8.  Drug disposition in patients with HBsAg-positive chronic liver disease.

Authors:  J P Villeneuve; M J Thibeault; M Ampelas; H Fortunet-Fouin; L LaMarre; J Côté; G Pomier-Layrargues; P M Huet
Journal:  Dig Dis Sci       Date:  1987-07       Impact factor: 3.199

9.  Pharmacokinetics of biliary excretion in man. VI. Indocyanine green.

Authors:  D K Meijer; B Weert; G A Vermeer
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

10.  Verapamil favorably influences hepatic microvascular exchange and function in rats with cirrhosis of the liver.

Authors:  J Reichen; M Le
Journal:  J Clin Invest       Date:  1986-08       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.